PEMOLINE TREATMENT OF DEFICIT SYMPTOMS IN SCHIZOPHRENIA

临床脑疾病分支从事一系列的临床 多巴胺激动剂的试验，以寻找治疗 精神分裂症的缺陷症状 这项工作的动力来自于 影像学研究显示，通过增强大脑皮层 多巴胺能功能缺陷症状可能得到改善。 匹莫林是一种间接多巴胺激动剂，长期用于治疗 儿童注意力缺陷障碍 它的安全记录 没有严重的毒性。 在实验动物中， 去甲肾上腺素能活性 此外，动物不会自行给药 药物，这表明它具有较低的成瘾性和滥用潜力。 这些特性使匹莫林与安非他明区别开来， 哌甲酯，最常用于儿童的多巴胺激动剂， 使匹莫林成为刺激皮质多巴胺的有吸引力的候选者 功能 一个开放的试验pemoline在病人是令人鼓舞的。 正式方案 正在准备一项双盲临床研究， 假设。

The Clinical Brain Disorders Branch is engaged in a series of clinical trials of dopamine agonists in an effort to find some treatment for the deficit symptoms of schizophrenia. The impetus for this work comes from evidence developed here from imaging studies that by enhancing cortical dopaminergic function deficit symptoms might be ameliorated. Pemoline is an indirect dopamine agonist long used in the treatment of attention deficit disorder in children. It has a track record of safety and lack of serious toxicity. In experimental animals it is devoid of noradrenergic activity. Additionally, animals will not self administer the drug, which suggests that it is has low addictive and abuse potential. These characteristics set pemoline apart from amphetamine and methylphenidate, the dopamine agonists most commonly used in children, and make pemoline an attractive candidate for stimulating cortical dopamine function. An open trial of pemoline in on patient was encouraging. A formal protocol is in preparation for a double blind clinical study to confirm or refuse the hypothesis.